{"title": "Nanoparticles", "author": null, "url": "https://www.helmholtz-hzi.de/en/info-centre/topics/anti-infectives/nanoparticles/", "hostname": "helmholtz-hzi.de", "description": "Changing the world with tiny particles? Not so unrealistic thanks to nanotechnology. Nanoparticles are so small that they can no longer be seen even under a light microscope. Despite their small size, however, nanoparticles already determine large parts of our everyday life.", "sitename": "Helmholtz Centre for Infection Research", "date": "2022-01-06", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Nano-particles - small, but powerful\nTheir enormous potential extends to a wide range of applications. Nanotechnology is used virtually everywhere, from the electronics industry, cosmetics and material sciences to medicine. The reason: Fundamental changes to chemical and physical properties can be made by treating materials with nano-particles.\nThese opportunities make the use of nano-particles interesting to physicians and biologists as well. For example, it may be possible to achieve improvements in areas such as the diagnostics and therapy of diseases as well as in active substance transport. Researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a branch of the Helmholtz Centre for Infection Research (HZI), are already exploiting the properties of nano-particles to date. HZI scientists have found a way to use nano-particles to transport vaccines in a closely controlled manner. They serve as a kind of packaging and transporter in this application. After suitable preparation, the particles penetrate through the hair follicles into the skin and burst upon contact with human sweat, which releases the\n[vaccine](/en/info-centre/glossary/entry/vaccine/). The advantage of this method is that the [vaccination](/en/info-centre/glossary/entry/vaccination/) via injection of a needle can be avoided and it may be possible in the future to vaccinate by simply applying a lotion to the skin.\nHowever, the transport function of nanoparticles is not only important for vaccines. They are also helpful in the active fight against tumour and infectious diseases. They are used as \"nano-capsules\" to transport agents specifically to the site at which they are meant to act in the body. This capability would be a decisive benefit in Chemotherapy. One undesired side effect of this therapy is that it damages not only tumour cells, but healthy tissue as well. If nano-capsules could be used to transport the agents to the afflicted regions exclusively, the undesired side effects could be prevented and the therapy would be gentler on the patient.\nBeyond all the excitement, there is also some concern about the use of nano-particles. One drawback is that the long-term impact on the human body has not been researched sufficiently yet because the technology is still so new. Regardless of their size, possible risks of certain nano-particles are determined firstly by the material of which they are made. So when nano-materials enter the body, this does not necessarily mean they are a hazard. For this reason, only materials that are harmless to the body and in most cases even biodegradable are used in the medical-pharmaceutical sector. Like with all medications, the use of nano-medications is subject to very strict international laws and rules.\nAudio Podcast\n- Eine Revolution in der Infektionsforschung \u2013 mit dem Immunsystem der Bakterien gegen Krankheitserreger ank\u00e4mpfenEtwas ganz Neues zu entdecken, einen v\u00f6llig neuen Weg einschlagen zu k\u00f6nnen, quer forschen zu d\u00fcrfen \u2013 die Chance haben nur wenige. Die Wissenschaftlerin Emmanuelle Charpentier war an so einer Innovation in der Forschung beteiligt. Sie hat einen Mechanismus mitentdeckt, der die Manipulation von Erbmaterial revolutioniert hat \u2013 egal zu welchem Zweck. Ob f\u00fcr die Erforschung von Krankheiten, die Behandlung von Gendefekten oder die Produktion von Joghurt. CRISPR stellt den Umgang mit Genen auf den Kopf. Ines Fonfara forscht an CRISPR \u2013 lassen Sie sich von ihr eine Revolution erkl\u00e4ren\u2026\n- Mit M\u00e4usekot gegen Morbus Crohn \u2013 neue Wege gegen chronisch-entz\u00fcndliche DarmerkrankungenEntz\u00fcndliche Darmerkrankungen bedeuten gro\u00dfes Leid f\u00fcr die Patienten, sind kaum behandelbar und bisher wissen weder \u00c4rzte noch Forscher, wie es dazu kommt, dass allein in Deutschland etwa 300.000 Menschen an Krankheiten wie Morbus Crohn und Colitis Ulcerosa leiden. Wissenschaftler am HZI suchen in den Bakteriengemeinschaften, die im Darm leben nach Antworten. Begleiten Sie Till Strowig ins Labor und h\u00f6ren Sie zu, wie er ein Probenr\u00f6hrchen voll M\u00e4usekot f\u00fcr die Forschung homogenisiert\u2026\n- BRICS \u2013 Rechnen f\u00fcr die InfektionsforschungDie Mischung macht es \u2013 im richtigen Leben ebenso wie in der Infektionsforschung. Systembiologen am HZI und an der Technischen Universit\u00e4t Braunschweig mischen Laborerkenntnisse mit Computermodellen. Begleiten Sie Michael Meyer-Hermann virtuell an das BRICS und h\u00f6ren Sie weshalb es so sinnvoll ist, Biologie mit System zu betreiben.\n- So stark wie ein Desinfektionsmittel \u2013 Muttermilch inaktiviert Hepatitis-C Viren\u201eBreast is Best\u201c \u2013 ein Slogan der f\u00fcr eine internationale Pro-Stillbewegung steht. Nur was ist, wenn die Mutter krank ist, und ihre Milch zum Risiko f\u00fcr ihr Baby werden k\u00f6nnte? Wissenschaftler an der HZI-Tochtereinrichtung TWINCORE haben untersucht, was mit Hepatitis-C Viren in Muttermilch geschieht, denn wenn eine Mutter mit dem Virus infiziert ist, k\u00f6nnte sie ihr Baby dar\u00fcber anstecken. Lassen Sie sich von Eike Steinmann und Stephanie Pf\u00e4nder erz\u00e4hlen, was f\u00fcr eine wundersame Fl\u00fcssigkeit Muttermilch ist\u2026\n- Gef\u00e4hrliche Spritzen \u2013 Salmonellen infizieren uns mit molekularen NadelnSalmonellen leben und t\u00f6ten \u00fcberall auf der Welt. Mehrere Hundert Millionen Kranke gehen j\u00e4hrlich weltweit auf ihr Konto.Die Strategien mit denen sie sich unseren Behandlungsversuchen entziehen, werden immer raffinierter, die Resistenzen gegen Antibiotika immer mehr. Marc Erhardt geht auf der Suche nach neuen Therapieans\u00e4tzen einen ungew\u00f6hnlichen Weg: Er untersucht das Spritzbesteck, mit dem Salmonellen uns infizieren und er sucht nach Ans\u00e4tzen, die die Bakterien nicht t\u00f6ten \u2013 und damit Resistenzen provozieren \u2013, sondern nur ihre Spritze verstopfen. Begleiten Sie Marc Erhardt in sein Labor\u2026\n- Ein neuer Impfstoff gegen Tuberkulose \u2013 die Infektion Nr. 1 in der WeltAlle 15 Sekunden stirbt ein Mensch an Tuberkulose. Bislang gibt es keinen ausreichend wirksamen Impfstoff gegen das Mycobacterium tuberkulosis, lediglich einen, der S\u00e4uglinge in den ersten zwei Lebensjahren sch\u00fctzt. Jetzt kristallisiert sich in klinischen Studien ein vielversprechender neuer Impfstoff heraus, den die Vakzine Projekt Management GmbH auf ihrem Weg zur Zulassung begleitet. Bernd Eisele und Leander Grode stellen Ihnen den Impfstoff vor und berichten von ihren Hoffnungen und Erwartungen\u2026\n- Sichere Forschung am HZI \u2013 eines der modernsten Labore der Schutzstufe 3Am HZI wurde 2013 ein neues Laborgeb\u00e4ude er\u00f6ffnet. F\u00fcr ein Forschungszentrum w\u00e4re das eigentlich nichts Besonderes \u2013 wenn da nicht die Schutzstufe 3 an der T\u00fcr st\u00e4nde. Wie ein S3-Labor funktioniert, was es so sicher macht und wie viel Technik hinter dieser Sicherheit steckt, erkl\u00e4rt Ihnen Dr. Susanne Talay. Sie leitet das Labor und f\u00fchrt Sie hindurch \u2013 nat\u00fcrlich bevor die wissenschaftlichen Arbeiten darin begonnen haben. Nutzen Sie die einmalige Chance hinter die T\u00fcren eines S3-Labors zu h\u00f6ren\u2026\n- R\u00f6ntgenstrahlen f\u00fcr neue Malaria-Medikamente \u2013 Ein energiereicher Blick auf den Bewegungsapparat von PlasmodienMalaria geh\u00f6rt zu den Infektionskrankheiten, die weltweit die meisten Todesopfer fordern. Am DESY in Hamburg untersucht eine Wissenschaftlerin des Helmholtz-Zentrums f\u00fcr Infektionsforschung die Tricks der Parasiten, die Malaria ausl\u00f6sen, und sie sucht nac\n- Mehrwert f\u00fcr klinische Studien - Frank Pessler im Gespr\u00e4ch \u00fcber ein Sechs-Millionen-Euro-ProjektEin vielversprechender Antibiotika-Kandidat wird in K\u00fcrze in klinischen Studien erprobt: Das Mittel tr\u00e4gt noch den kryptischen Arbeitsnamen \"GSK1322322\" und wurde von dem britischen Pharmaunternehmen GlaxoSmithKline entwickelt. W\u00e4hrend klinischer Studien mit neuen Medikamenten gewinnen Mediziner gro\u00dfe Mengen Patientenproben, die einen unsch\u00e4tzbaren Wert f\u00fcr die Erforschung der Krankheiten haben, an denen die Patienten leiden - und bislang nur selten genutzt werden. Der Projekt-Koordinator Frank Pessler im Gespr\u00e4ch \u00fcber die Hintergr\u00fcnde.\n- Gas und Bremse f\u00fcr ImmunantwortenUnser Immunsystem ist gepr\u00e4gt durch ein kompliziertes Wechselspiel unterschiedlicher Immunzellen, das Wissenschaftler st\u00fcckchenweise verstehen lernen. Um das Immunsystem daran zu hindern, dass es sich gegen uns selbst richtet oder um ihm auch mal einen Schubs geben zu k\u00f6nnen, m\u00fcssen sie die molekularen Stellkn\u00f6pfe finden \u2013 und beeinflussen. Einen dieser Stellkn\u00f6pfe haben Ingo Schmitz und Marc Schuster entdeckt. Folgen Sie den beiden ins Labor...\nResearch at HZI\nResearch Groups\n[Send per email](mailto:?subject=&body=https://www.helmholtz-hzi.de/en/info-centre/topics/anti-infectives/nanoparticles/)Share", "language": null, "image": "https://www.helmholtz-hzi.de/fileadmin/user_upload/Infothek/Themen/Nanopartikel.jpg", "pagetype": null, "links": ["/en/", "/de/wissen/wissensportal/neue-wirkstoffe/nanoparticles/", "/en/the-hzi/", "/en/the-hzi/about-the-hzi/facts-and-figures/", "/en/the-hzi/about-the-hzi/the-hzi/", "/en/the-hzi/about-the-hzi/facts-and-figures/", "/en/the-hzi/about-the-hzi/research-reports/", "/en/the-hzi/about-the-hzi/history-1965-2006/", "/en/the-hzi/about-the-hzi/history-since-2006/", "/en/the-hzi/management/executive-management/", "/en/the-hzi/administration-infrastructure/", "/en/the-hzi/organisation-chart/", "/en/the-hzi/sites/", "/en/the-hzi/360-tour/", "/en/the-hzi/helmholtz-association/", "http://helmholtz-hzi.bibliotheca-open.de/Welcome", "/en/the-hzi/conference-building/", "/en/the-hzi/friends-of-the-hzi/", "/en/the-hzi/mission-statement/", "/en/the-hzi/gender-equality/gender-equality/", "/en/the-hzi/conflict-resolution/", "/en/the-hzi/donation/", "/en/research/research-topics/", "/en/research/mission/", "/en/research/our-research/", "/en/research/research-topics/", "/en/research/research-topics/bacterial-and-viral-pathogens/", "/en/research/research-topics/immune-response/", "/en/research/research-topics/anti-infectives/", "/en/research/research-foci/", "/en/research/research-foci/antimicrobial-resistance-amr/", "/en/research/research-foci/microbial-communities-mico/", "/en/research/research-foci/chronic-viral-infections-cvir/", "/en/research/research-foci/individualized-immune-interventions-indi/", "/en/research/research-foci/digital-and-global-health-epi/", "/en/research/research-foci/infection-and-neurodegeneration-ineu/", "/en/research/research-foci/respiratory-viral-infections-rvir/", "/en/research/research-groups/", "/en/research/technology-platforms/", "/en/research/innovation-management/", "/en/research/cooperations/research-partners/", "/en/research/publication-database/", "/en/research/good-scientific-practice/", "/fileadmin/user_upload/Infothek/Roadmap_HZI_2025/Roadmap_engl_2016_WEB_ES.pdf", "/en/research/translational-research/", "/fileadmin/user_upload/Infothek/Ueber_das_HZI/Jahresberichte/Ergebnisberichte/WEB_HZI_RReport_2022_9MB.pdf", "/fileadmin/user_upload/Infothek/Ueber_das_HZI/Jahresberichte/Ergebnisberichte/WEB_HZI_RReport_2022_9MB.pdf", "/en/career/", "/en/career/jobs/open-positions/", "/en/career/jobs/open-positions/", "/en/career/jobs/phd-theses/", "/en/career/jobs/bachelor-and-master-thesis/", "/en/career/career-paths/", "/en/career/graduate-school/application/", "/en/career/phd-programme-epidemiology/objectives/", "/en/career/embl-hzi-fellowship/general-information/", "/en/career/hzi-mcgill-exchange-program/about-the-program/", "/en/career/do-it-phd-initiative/what-we-do/", "/en/career/hzi-alumni/aims/", "/en/career/pupils/apprenticeships/", "/en/career/career-paths/", "/en/press/", "/en/press/press-releases-news/", "/en/press/gallery-download/", "/en/press/press-kit-josef-penninger/", "/en/press/media-coverage/", "/en/service/newsletter/", "/en/press/press-contacts/", "/en/press/videos-podcasts/videos/", "/en/press/magazine-infact/recent-issue/", "/en/press/brochures/", "/en/press/visitors-service/", "/en/press/press-kit-josef-penninger/", "/en/press/press-kit-josef-penninger/", "/en/info-centre/", "/en/info-centre/topics/all-topics/", "/en/info-centre/topics/germs-and-diseases/", "/en/info-centre/topics/our-immune-system/", "/en/info-centre/topics/anti-infectives/", "/en/press/videos-podcasts/videos/", "/en/info-centre/glossary/", "/en/info-centre/topics/germs-and-diseases/coronaviruses/", "/en/news-events/", "/en/news-events/news/", "/en/news-events/events/", "/en/news-events/research-awards/paper-of-the-month/", "/en/news-events/projects/", "/en/news-events/projects/discourse-animals-in-research/", "/en/news-events/stories/", "/en/news-events/stories/world-day-for-laboratory-animals-and-alternative-models/", "/en/news-events/stories/world-antibiotic-awareness-week-2022/", "/en/news-events/stories/one-health-triad-of-environmental-animal-and-human-health/", "/en/news-events/interview/", "/en/news-events/interview/martin-korte-long-covid-can-become-manifest-even-after-a-mild-course-of-covid-19/", "/en/news-events/interview/peggy-riese-the-corona-vaccines-were-meant-to-protect-against-severe-disease-and-that-is-what-they-do/", "/en/news-events/portrait/", "/en/news-events/portrait/christian-sieben-a-biologist-with-nano-vision/", "/en/news-events/portrait/susanne-talay-a-little-outbreak-every-day/", "/en/news-events/portrait/antoine-emmanuel-saliba-shining-a-spotlight-on-the-cellular-mechanism/", "/en/news-events/stories/coronavirus-sars-cov-2/", "/en/news-events/stories/coronavirus-sars-cov-2/", "/en/", "/en/info-centre/", "/en/info-centre/topics/all-topics/", "/en/info-centre/topics/anti-infectives/", "/en/info-centre/topics/germs-and-diseases/#anchorsection", "/en/info-centre/topics/our-immune-system/#anchorsection", "/en/info-centre/topics/anti-infectives/#anchorsection", "/fileadmin/user_upload/Infothek/Themen/Nanopartikel.jpg", "/en/info-centre/glossary/entry/vaccine/", "/en/info-centre/glossary/entry/vaccination/", "/en/news-events/news/view/article/complete/fabian-leendertz-erhaelt-den-hamburger-wissenschaftspreis-2023-zum-thema-one-health/", "/en/news-events/news/view/article/complete/der-faktor-mensch/", "/en/news-events/news/view/article/complete/microbelix-erobert-das-saarland/", "/en/research/research-topics/anti-infectives/biological-barriers-and-drug-delivery/", "javascript:if(window.print)window.print()", "mailto:?subject=&body=https://www.helmholtz-hzi.de/en/info-centre/topics/anti-infectives/nanoparticles/", "https://www.facebook.com/sharer/sharer.php?u=https://www.helmholtz-hzi.de/en/info-centre/topics/anti-infectives/nanoparticles/%2F&src=sdkpreparse", "https://twitter.com/intent/tweet?text=Check%20this%20page%20https://www.helmholtz-hzi.de/en/info-centre/topics/anti-infectives/nanoparticles/", "/en/press/", "https://buendnis.niedersachsen.de/startseite/", "https://www.helmholtz-klima.de/en", "https://www.charta-der-vielfalt.de/en/", "https://www.initiative-transparente-tierversuche.de/", "https://www.facebook.com/helmholtz.hzi", "https://twitter.com/Helmholtz_HZI", "https://de.linkedin.com/company/helmholtz-centre-for-infection-research", "https://www.youtube.com/channel/UC1P_GFvzrKeCgD4z4h4sKDQ", "/en/service/feeds/", "/en/service/newsletter/", "tel:+495316181-0", "/en/nc/service/contact/person/helmholtz-centre-for-infection-research-hzi/", "tel:+49531-6181-0", "/en/nc/service/contact/person/helmholtz-centre-for-infection-research-hzi/", "/en/the-hzi/sites/campus-braunschweig/", "tel:+49-531-391-55100", "/en/nc/service/contact/person/braunschweig-integrated-centre-of-systems-biology-brics/", "/en/the-hzi/sites/braunschweiger-integrated-centre-of-systems-brics/about-brics/", "tel:+49-511-220027-0", "/en/nc/service/contact/person/twincore-centre-for-experimental-and-clinical-infection-research/", "/en/the-hzi/sites/twincore-centre-for-experimental-and-clinical-infection-research/about-twincore/", "tel:+49-511-5350-8500", "/en/nc/service/contact/person/hzi-study-centre/", "/en/the-hzi/sites/study-centre-crc/", "tel:+49-511-5350-8658", "/en/nc/service/contact/person/centre-for-individualised-infection-medicine-ciim/", "/en/the-hzi/sites/centre-for-individualised-infection-medicine-ciim/", "tel:+49-40-8998-3672", "/en/nc/service/contact/person/centre-for-structural-systems-biology-cssb/", "/en/the-hzi/sites/centre-for-structural-systems-biology-cssb/", "tel:+49-681-98806-0", "/en/nc/service/contact/person/helmholtz-institute-for-pharmaceutical-research-saarland-hips/", "/en/the-hzi/sites/helmholtz-institute-for-pharmaceutical-research-saarland-hips/about-hips/", "tel:+49-931-31-89587", "mailto:info@helmholtz-hiri.de", "/en/the-hzi/sites/helmholtz-institute-for-rna-based-infection-research-hiri/", "tel:+49-3834-420-5501", "mailto:hioh-info@helmholtz-hzi.de", "/en/the-hzi/sites/helmholtz-institute-for-one-health-hioh/", "/en/the-hzi/sites/campus-braunschweig/", "/en/the-hzi/sites/braunschweiger-integrated-centre-of-systems-brics/about-brics/", "/en/the-hzi/sites/helmholtz-institute-for-pharmaceutical-research-saarland-hips/about-hips/", "/en/the-hzi/sites/twincore-centre-for-experimental-and-clinical-infection-research/about-twincore/", "/en/the-hzi/sites/study-centre-crc/", "/en/the-hzi/sites/centre-for-individualised-infection-medicine-ciim/", "/en/the-hzi/sites/centre-for-structural-systems-biology-cssb/", "/en/the-hzi/sites/helmholtz-institute-for-one-health-hioh/", "/en/the-hzi/sites/helmholtz-institute-for-rna-based-infection-research-hiri/", "/en/nc/service/contact/", "/en/service/imprint/", "/en/service/sitemap/", "/en/service/newsletter/", "/en/service/data-protection/", "https://whistlefox.heuking.de/start/hzi-gmbh/en", "https://www.helmholtz.de"]}